'Clinical trials related to TB permitted on children'

Image
IANS New Delhi
Last Updated : Aug 08 2017 | 7:32 PM IST

The approval for clinical trials of various antibiotics on children under one years of age were mainly related to trials of Multi-Drug Resistant Tuberculosis and Tuberculosis Meningitis in children, parliament was informed on Tuesday.

The approval was granted by the Central Licencing Authority and the details of the clinical trials are registered with Clinical Trial Registry of India, publicly available on www.ctri.nic.in.

In a written reply in the Rajya Sabha, Minister of State for Health and Family Welfare Faggan Singh Kulaste said that use of antibiotics is a major driver of resistance.

"Neonates are more prone to infections and vulnerable to ineffective treatment. Sepsis remains a leading cause of mortality and morbidity, especially during the first five days of life and in low and middle-income countries," said Kulaste.

Antibiotics are included in Schedule H and H1 to the Drugs & Cosmetics Rules, 1945, and therefore cannot be sold in retail except on and in accordance with the prescription of a registered medical practitioner.

Indian Council of Medical Research has launched a programme on Antimicrobial Stewardship, Prevention of Infection and Control in 2012.

Functional infection control programmes not only cut down the rates of nosocomial infections, but also reduce the volume of antibiotic consumption and are a critical part of any comprehensive strategy to contain antimicrobial resistance.

"Further, a red line campaign has been launched to regulate over the counter sale of Schedule H antibiotics. The campaign is aimed at discouraging unnecessary prescription and over-the-counter sale of antibiotics causing drug resistance for several critical diseases including TB, malaria, urinary tract infection and even HIV," said Kulaste.

--IANS

rup/him/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 08 2017 | 7:24 PM IST

Next Story